Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

More Resources Sought For Using Patient-Preference Data In Device Reviews

This article was originally published in The Gray Sheet

Executive Summary

Some device user fee revenue could be used to enhance application of patient-preference data, FDA said at a recent meeting of patient and consumer groups about user-fee reauthorization. Several groups urged greater emphasis in that area at the closed-door meeting, and some groups also pushed for increasing device user fees closer to the much higher levels charged to drug firms.


Related Content

Industry Challenges FDA's User Fee Markup
FDA Launches Patient Engagement Advisory Committee For Devices
Calls For More FDA Training In Lead Up To User-Fee Negotiations